DrugCite
Search

INIPOMP

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Inipomp Adverse Events Reported to the FDA Over Time

How are Inipomp adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Inipomp, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Inipomp is flagged as the suspect drug causing the adverse event.

Most Common Inipomp Adverse Events Reported to the FDA

What are the most common Inipomp adverse events reported to the FDA?

Hyponatraemia
77 (2.68%)
Thrombocytopenia
68 (2.36%)
Renal Failure Acute
64 (2.22%)
Agranulocytosis
42 (1.46%)
Cytolytic Hepatitis
34 (1.18%)
Pancytopenia
34 (1.18%)
Pyrexia
32 (1.11%)
Diarrhoea
29 (1.01%)
Neutropenia
29 (1.01%)
Cholestasis
28 (.97%)
Drug Interaction
28 (.97%)
Show More Show More
General Physical Health Deteriorati...
28 (.97%)
Renal Failure
27 (.94%)
Toxic Epidermal Necrolysis
27 (.94%)
Condition Aggravated
26 (.9%)
Drug Rash With Eosinophilia And Sys...
26 (.9%)
Malaise
26 (.9%)
Vomiting
26 (.9%)
Confusional State
25 (.87%)
Pruritus
25 (.87%)
Anaemia
24 (.83%)
Blood Creatine Phosphokinase Increa...
23 (.8%)
Dyspnoea
21 (.73%)
Myalgia
21 (.73%)
Fall
20 (.69%)
Inflammation
19 (.66%)
Toxic Skin Eruption
19 (.66%)
Aspartate Aminotransferase Increase...
18 (.63%)
Dehydration
18 (.63%)
Nausea
18 (.63%)
Purpura
18 (.63%)
Alanine Aminotransferase Increased
17 (.59%)
Asthenia
17 (.59%)
Leukopenia
17 (.59%)
Pancreatitis Acute
17 (.59%)
Jaundice
16 (.56%)
Loss Of Consciousness
16 (.56%)
Pleural Effusion
16 (.56%)
Rash Papular
16 (.56%)
Vertigo
16 (.56%)
Convulsion
15 (.52%)
Dermatitis Bullous
15 (.52%)
Eosinophilia
15 (.52%)
Hepatitis Cholestatic
15 (.52%)
Dermatitis Exfoliative
14 (.49%)
Hypokalaemia
14 (.49%)
Pulmonary Embolism
14 (.49%)
Rash Erythematous
14 (.49%)
Tumour Lysis Syndrome
14 (.49%)
Axonal Neuropathy
13 (.45%)
Blood Creatinine Increased
13 (.45%)
Cardiac Failure
13 (.45%)
Renal Failure Chronic
13 (.45%)
Septic Shock
13 (.45%)
Anorexia
12 (.42%)
Deep Vein Thrombosis
12 (.42%)
Drug Ineffective
12 (.42%)
Face Oedema
12 (.42%)
Gamma-glutamyltransferase Increased
12 (.42%)
Gastrointestinal Haemorrhage
12 (.42%)
Hepatocellular Injury
12 (.42%)
Thrombocytopenic Purpura
12 (.42%)
Aphthous Stomatitis
11 (.38%)
Bone Marrow Failure
11 (.38%)
Haemorrhagic Disorder
11 (.38%)
Hallucination
11 (.38%)
Hyperuricaemia
11 (.38%)
Mouth Haemorrhage
11 (.38%)
Multi-organ Failure
11 (.38%)
Overdose
11 (.38%)
Rash Macular
11 (.38%)
Weight Decreased
11 (.38%)
Death
10 (.35%)
Eczema
10 (.35%)
Haematuria
10 (.35%)
Histiocytosis Haematophagic
10 (.35%)
International Normalised Ratio Incr...
10 (.35%)
Lipase Increased
10 (.35%)
Lymphopenia
10 (.35%)
Orthostatic Hypotension
10 (.35%)
Rash Maculo-papular
10 (.35%)
Somnolence
10 (.35%)
C-reactive Protein Increased
9 (.31%)
Encephalopathy
9 (.31%)
Haemorrhage
9 (.31%)
Hypotension
9 (.31%)
Aphasia
8 (.28%)
Arthritis
8 (.28%)
Cataract
8 (.28%)
Disorientation
8 (.28%)
Disseminated Intravascular Coagulat...
8 (.28%)
Epistaxis
8 (.28%)
Headache
8 (.28%)
Hyperkalaemia
8 (.28%)
Insomnia
8 (.28%)
Interstitial Lung Disease
8 (.28%)
Myoclonus
8 (.28%)
Oedema Peripheral
8 (.28%)
Platelet Count Decreased
8 (.28%)
Vitamin K Deficiency
8 (.28%)
Acute Generalised Exanthematous Pus...
7 (.24%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Inipomp, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Inipomp is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Inipomp

What are the most common Inipomp adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Inipomp, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Inipomp is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Inipomp According to Those Reporting Adverse Events

Why are people taking Inipomp, according to those reporting adverse events to the FDA?

Drug Use For Unknown Indication
230
Prophylaxis
65
Product Used For Unknown Indication
44
Gastrooesophageal Reflux Disease
37
Prophylaxis Against Gastrointestina...
32
Abdominal Pain Upper
31
Show More Show More
Gastric Ulcer
19
Gastritis
14
Hiatus Hernia
12
Unevaluable Event
12
Oesophagitis
12
Gastroduodenal Ulcer
11
Peptic Ulcer
9
Gastric Disorder
8
Helicobacter Infection
7
Ill-defined Disorder
7
Ulcer
6
Duodenal Ulcer
6
Hypertension
5
Gastrointestinal Haemorrhage
5
Reflux Gastritis
5
Helicobacter Gastritis
4
Gastric Haemorrhage
4
Dyspepsia
4
Myocardial Infarction
3
Joint Sprain
3
Diaphragmatic Hernia
3
Perforated Ulcer
3
Gastrointestinal Disorder
3
Gastrooesophageal Reflux Prophylaxi...
2
Oesophageal Ulcer
2
Duodenitis
2
Gastritis Prophylaxis
2
Colitis
2
Regurgitation
2
Pain
2
Asthma
2
Cholecystitis Acute
2
Thrombosis Prophylaxis
1
Abdominal Pain
1
Melaena
1
Acute Coronary Syndrome
1
Crohns Disease
1
Rheumatoid Arthritis
1
Ischaemic Cardiomyopathy
1
Cholecystitis
1
Gastroenteritis
1
Gastric Cancer
1
Ankylosing Spondylitis
1
Cerebrovascular Accident
1
Gastrointestinal Disorder Therapy
1

Inipomp Case Reports

What Inipomp safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Inipomp. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Inipomp.